Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 15/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 14/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 10/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18769587 | 0.96 | SLC6A4 (0.59) | SLC6A4SLC6A3SLC6A2 | |
| Hydrochloric Acid SCHEMBL18742610 | 0.94 | SLC6A4 (0.58) | SLC6A4SLC6A3SLC6A2KCNH2 | |
| SCHEMBL3849372 | 0.91 | SLC6A4 (0.53) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL16649648 | 0.82 | SLC6A4 (0.53) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL12497571 | 0.80 | OPRM1 (0.59) | SLC6A4SLC6A3SLC6A2KCNH2 | |
| SCHEMBL18769437 | 0.79 | SLC6A3 (0.57) | SLC6A4SLC6A3SLC6A2 | |
| Hydrochloric Acid SCHEMBL18742787 | 0.77 | SLC6A3 (0.55) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL8478708 | 0.76 | SLC6A4 (0.53) | SLC6A4SLC6A3 | |
| SCHEMBL3519636 | 0.75 | SLC6A3 (1.00) | SLC6A4SLC6A3SLC6A2 | |
| Hydrochloric Acid SCHEMBL18662772 | 0.74 | SLC6A4 (0.52) | SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389559-B2 | Pyrrolidine triple reuptake inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-20120022125-A1 | PYRROLIDINE TRIPLE REUPTAKE INHIBITORS | SUNOVION PHARMACEUTICALS INC. | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022125-A1 | PYRROLIDINE TRIPLE REUPTAKE INHIBITORS | SLC18A2, SLC6A2, SLC6A3 | SLC6A4 4/4885SLC6A3 3/4885SLC6A2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.